Patients and methods
PB_2017-00621) and Swissmedic (Ref.
We conducted a prospective and randomised phase I clinical trial using ultrasound-guided injections of autologous MPCs into the EUS. The aim of the study was to assess the safety and feasibility of this autologous cell therapy for the treatment of SUI in female patients. The local ethics committee (KEK-ZH-Nr. 2014-0547, BASEC Nr. PB_2017-00621) and Swissmedic (Ref. Nr. 2014TpP1009) both approved the phase I study, and the trial was registered on 